Leukemia Treatment: Adding an Antibody to Front-Line Chemotherapy
Research Question:
What are the side effects of a monoclonal antibody, inotuzumab ozogamicin, and how
well does it work when given with front-line chemotherapy in treating patients with
newly diagnosed B acute lymphoblastic leukemia.
Basic Study Information
Purpose:
Monoclonal antibodies, such as inotuzumab ozogamicin, may block cancer growth in different
ways by targeting certain cells. Drugs used in chemotherapy work in different ways
to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin with chemotherapy
may work better in treating young adults with B acute lymphoblastic leukemia. This
trial studies the side effects of inotuzumab ozogamicin and how well it works when
given with front-line chemotherapy in treating patients with newly diagnosed B acute
lymphoblastic leukemia.
Location: University of Rochester Medical Center
Study Reference #: CLEU18093
Lead Researcher (Principal Investigator)
Lead Researcher: Kristen O'Dwyer
Study Contact Information
Study Coordinator: Haley Misch
Phone: (585) 275-9485
Email: Haley_Misch@URMC.Rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search